NCT06009497View on ClinicalTrials.gov

Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Non Severe Aplastic Anemia
Interventions
DRUG

Romiplostim

Romiplostim 10 µg/kg, subcutaneous injection, once a week.

DRUG

Ciclosporin

Ciclosporin 3-5mg/kg/d, adjust the dose to keep trough ciclosporin plasma concentration 100-200ng/ml.

Trial Locations (1)

Unknown

Peking union medical college hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06009497 - Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA | Biotech Hunter | Biotech Hunter